Hope for powerful new C diff. treatment

September 19, 2011

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

The Glasgow-based company is working on a new compound which has proved to be more effective in killing and preventing C diff. than , currently one of the most widely used treatments against this bacterium.

The company has selected the compound, MGB BP-3, as a drug candidate for formal pre-clinical development, with clinical trials now scheduled for 2012.

The compound acts in minor grooves, found within , and has potential to act as an agent against bacteria including C. diff. and MRSA.

C. diff. was involved in more than 3,000 deaths in the UK in 2010.

The findings of the research are being presented on Monday, 19 September, at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Chicago.

Dr Miroslav Ravic, Chief Executive Officer of MGB Biopharma, said: "It seems we are hearing too much about Clostridium difficile infections these days in the press, especially those acquired in hospital by elderly patients in whom the infection can be fatal.

"This is clearly an area of high unmet need as a result of the rise of which are threatening to outpace the availability of able to successfully treat these life- threatening infections. We are very excited that MGB BP-3 shows such a promising response against this troublesome and difficult to treat infection.

"We are committed to developing a specific for the treatment of Clostridium difficile infections in addition to the progress we are making with an IV drug against MRSA."

Professor Colin Suckling, of the University of Strathclyde's Department of Pure and Applied Chemistry, is Principal Investigator in the DNA minor groove binder technology. He said: "C. diff. infections can kill and patients can face prolonged courses of treatment to deal with them.

"We have come up with strong compounds which are capable not only of clearing the infections but also of stopping them. We believe this could be a significant step forward in tackling these dangerous infections."

Professor Curtis Gemmell, Consultant Microbiologist, Research Professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences and Emeritus Professor at the University of Glasgow, is a senior member of the research team. He said: "The fact that our shows greater efficacy than vancomycin is extremely promising for its future. The fact we are making this presentation at ICAAC underscores the importance that our scientific peers attach to our findings."

Related Stories

Recommended for you

Listeria may be serious miscarriage threat early in pregnancy

February 21, 2017

Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine ...

Ebola linked to habitat destruction

February 20, 2017

A Massey University veterinary scientist has co-authored research suggesting that Ebola virus emergence is linked to the clearing of animal habitat through deforestation in West and Central Africa.

New study determines how long Zika remains in body fluids

February 20, 2017

A study published in the New England Journal of Medicine provides evidence that the Zika virus particles remain longer in blood than in urine and some other body fluids. This information suggests that blood serum may be the ...

Researcher helps stem the spread of superbugs

February 20, 2017

Katherine Baker feels vindicated. She and other microbiologists have been warning for years that anti-bacterial soaps containing triclosan are bad for the environment, harmful for health, and do nothing to prevent disease.

Scientists uncover how Zika virus causes microcephaly

February 17, 2017

A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered the mechanisms that the Zika virus uses to alter brain development. These findings are detailed in Stem Cell Reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.